Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes

摘要: 1096 www.thelancet.com Vol 384 September 20, 2014 Holman and colleagues raise the possibility that metformin showed some effi cacy in UKPDS34 trial, which only compared 342 patients with 411 controls, yet their review strategy included randomised clinical trials more than 1000 patients. This efficacy was limited to a subgroup of overweight not significant at 1% level as planned protocol. Moreover, meta-analysis, proven. The comparison metformin–sulfonylurea combination sulfonylurea alone an increase all cause cardiovascular mortality, similarly reported UKPDS34, did comment on this point. We fi nd it peculiar whole medical community judges gold-standard treatment when its endpoints is based one result, obtained low-level proof. With regards long-term control glycaemia, quoted 10 year follow-up UKPDS, does have strong evidence, without mentioning ACCORD post-trial excess mortality persisted. time has come measure antidiabetics clinically important outcomes limit research safety studies.